Takeda Pharmaceutical Company Limited (4502) Earnings Releases & Disclosures
| Date | Type | Title | Files |
|---|---|---|---|
| 2026-09-14 | — | U.S. FDA Accepts New Drug Application Under Priority Review for Takeda’s Zasocitinib in Moderate-to-Severe Plaque Psoriasis | |
| 2026-08-29 | — | Takeda Receives U.S. FDA Approval of MIMRYLO (rusfertide), Marking a Potential Shift in the Treatment Paradigm for Polycythemia Vera | |
| 2026-08-06 | — | U.S. FDA Approves Takeda’s ORZEYFUL (oveporexton), the First and Only Medicine to Treat the Underlying Cause of Narcolepsy Type 1 | |
| 2026-07-30 | Earnings Release | Earnings Report (Kessan Tanshin) for the Three-month Period Ended June 30, 2026 (IFRS, Consolidated) |
TDnet keeps only 31 days; this site accumulates daily and cannot backfill earlier disclosures.